Total Funding
72
62
Total FundingPost-IPO Debt raised
Growth Score
-13 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
4251
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
- Donn Casale: PresidentPast Role: Dynavax Technologies, Chief Commercial Officer
- Richard Lowenthal: President and Chief Executive OfficerPast Role: Maxim Pharmaceuticals, Head (VP) of Regulatory Affairs
About the Company
ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening
anaphylaxis.
Women Founded
